FDA Clears Latest Version of Mobile Imaging App
The U.S. Food and Drug Administration has cleared the new version of MIM Software’s mobile imaging app, which is now approved for diagnostic X-ray and ultrasound viewing, the company announced.
The U.S. Food and Drug Administration has cleared the new version of MIM Software’s mobile imaging app, which is now approved for diagnostic X-ray and ultrasound viewing, the company annouced.
Mobile MIM is also cleared for radiation treatment plan review and approval, the company said. Mobile MIM received FDA 510(k) clearance in February 2011, becoming the first diagnostic radiology app approved for viewing images and medical diagnoses based on CT, MRI, and nuclear medical technology.
Jerimy Brockway, software director at MIM, called the addition of viewing X-ray on a handheld device “a milestone for mobile health.” Mobile MIM can display images of more than 25 megapixels.
Mobile MIM is a thick client that brings the data to the device for fast manipulation independent of network performance, according to the company. Device-level hardware encryption provides security for HIPAA compliance, and users can remove data from the device after viewing.
Study Explores Impact of Insurance on Treatment and Referrals for Patients with Uterine Fibroids
February 19th 2025Women with uterine fibroids and Medicaid coverage are significantly more likely to be treated with uterine artery embolization than those with commercial insurance, according to newly published research.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
